Аннотация
Список литературы
Цель. Проанализировать данные об использовании белков крови – традиционных онкомаркеров в диагностике и прогнозировании возврата заболевания при немелкоклеточном раке легкого. Результаты. В обзоре обобщены данные литературных источников об использовании опухолеассоциированных белков крови CYFRA 21-1 (фрагмент цитокератина 19), SCC (антиген плоскоклеточной карциномы), NSE (нейрон-специфическая енолаза), РЭА (раковый эмбриональный антиген), ПКM2 (пируваткиназа М2) и ProGRP (пептид, высвобождающий прогастрин) в качестве биомаркеров диагностики и прогнозировании возврата заболевания при немелкоклеточном раке легкого. Выводы. Традиционные онкомаркеры обладают невысокой эффективностью в диагностике и прогнозировании возврата заболевания при немелкоклеточном раке легкого.
Ключевые слова:
белки крови, традиционные онкомаркеры, немелкоклеточный рак легкого.
Using blood proteins – traditional tumor markers in diagnosis and prognosis of disease recurrence in non-small cell lung cancer
Objective. To analyze data on the use of blood proteins, traditional cancer markers, in the diagnosis and prediction of disease recurrence in non–small cell lung cancer. Results. The review summarizes literature data on the use of tumor-associated blood proteins CYFRA 21-1 (cytokeratin fragment 19), SCC (squamous cell carcinoma antigen), NSE (neuron-specific enolase), REA (cancer embryonic antigen), PKM2 (pyruvate kinase M2) and ProGRP (progastrin releasing peptide) as biomarkers for diagnosis and prognosis the return of the disease in non-small cell lung cancer. Conclusions. Traditional cancer markers are not very effective in diagnosing and predicting the return of the disease in non-small cell lung cancer.
Keywords
blood proteins, traditional tumor markers, non-small cell lung cancer.
-
1. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients / B.-Y. Wang [et al.] // Journal of Cancer Research and Clinical Oncology. – 2020. – Vol. 146, № 1. – P. 43–52. 2. National Cancer Institute: [site]. – Seattle, 2024. – URL: https://seer.cancer.gov/archive/csr/1975_2016/results_merged/ sect_15_lung_bronchus.pdf (date of access: 12.05.2025). 3. Клинический протокол «Алгоритмы диагностики и лечения злокачественных новообразований»: постановле- ние Министерства здравоохранения Республики Беларусь от 06.07.2018 № 60 // Национальный правовой интернетпортал Республики Беларусь. – URL: https://oncopatient.by/ wp-content/uploads/2019/06/W21833500p_1539378000.pdf? ysclid=m3izuz7956174193665 (дата обращения: 05.12.2025). 4. Олигометастатический немелкоклеточный рак легкого: определение понятия, критерии диагностики, современ- ные подходы к лечению / П. Е. Короткевич, В. Т. Малькевич, А. Н. Курченков, С. А. Зарембо // Онкологический журнал. – 2020. – Т. 14, № 2–3. – С. 141–146. 5. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer / K. Matsuoka, S. Sumitomo, N. Nakashima [et al.] // European Journal of Cardio-Thoracic Surgery. – 2007. – Vol. 32, № 3. – P. 435–439. 6. Руководство по онкологии / под ред. О. Г. Суконко. – Минск: Беларуская Энцыклапедыя iмя Петруся Броўкi, 2015. – 679 с. 7. Risk factors for tumor recurrence in patients with earlystage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification / R. Maeda, J. Yoshida, G. Ishii [et al.] // Chest. – 2011. – Vol. 140, № 6. – P. 1494–1502. 8. Tumor biomarkers for diagnosis, prognosis and targeted therapy / Y. Zhou, L. Tao, J. Qiu [et al.] // Signal Transduction and Targeted Therapy/ – 2024. – Vol. 9, № 1. – Р. 132. – doi: 10.1038/s41392-024-01823-2. 9. Курчин, В. П. Размер опухоли как прогностический фактор у радикально оперированных пациентов с немелкоклеточным раком легкого / В. П. Курчин, В. В. Гапеенко, Т. Б. Ипатий // Онкологический журнал. – 2019. – Т. 13, № 3. – С. 7–16. 10. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer / J. M. Bonfrer, K. N. Gaarenstroom, G. G. Kenter [et al.] // Gynecologic Oncol. – 1994. – Vol. 55, № 1. – Р. 371–375. 11. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer / J. L. Pujol, J. Grenier, J. P. Daures [et al.] // Cancer Research. – 1993. – Vol. 53, № 1. – P. 61–66. 15. Nakamura, H. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer / H. Nakamura, T. Nishimura // Surgery Today. – 2017. – Vol. 47, № 9. – Р. 1037–1059. 16. Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib / M. Jung, S. H. Kim, Y. J. Lee [et al.] // Experimental and Therapeutic Medicine. – 2011. – Vol. 2, № 4. – Р. 685–693. 17. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in nonsmall-cell lung cancer harboring EGFR mutation / K. Tanaka, A. Hata, R. Kaji [et al.] // Journal of Thoracic Oncology. – 2013. – Vol. 8, № 7. – P. 892–898. 18. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection / J. J. Yeh, F. Y. Liu, W. H. Hsu [et al.] // Lung. – 2002. – Vol. 180, № 5. – P. 273–279. 19. Inflammation and cancer / N. Singh, D. Baby, J. P. Rajguru [et al.] // Annals of African Medicine. – 2019. – Vol. 18, № 3. – P. 121–126. 20. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer / J. L. Pujol, X. Quantin, W. Jacot [et al.] // Lung Cancer. – 2003. – Vol. 39, № 2. – P. 131–138. 21. Murakami, A. Involvement of squamous cell carcinoma antigen in invasion and metastasis of squamous cell carcinoma of uterine cervix / A. Murakami, K. Yoshidomi, N. Sugino // Semantic scholar. – 2012. – URL: https://www.semanticscholar. org/reader/3f6eb411ce8aa326a451ee1d10d52d01d049ca0a (date of access: 03.05.2025). 22. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer / S. Ando, H. Kimura, N. Iwai [et al.] // Anticancer Research. – 2001. – Vol. 21, № 4В. – P. 3085–3092. 23. Comparative analysis of CEA and SCC serum markers with IAP in human lung cancer / M. Castelli, F. Salvati, A. Cruciani [et al.] // International Journal of Biological Markers. – 1989. – Vol. 4, № 1. – P. 45–50. 24. Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer / J. J. Body, J. P. Sculier, N. Raymakers [et al.] // Cancer. – 1990. – Vol. 65, № 7. – P. 1552–1556. 25. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure / F. Nomura, A. Koyama, M. Ishijima [et al.] // Oncology Reports. – 1998. – Vol. 5, № 2. – P. 389–392. 26. Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients / D. Yu, K. Du, T. Liu, G. Chen // International Journal of Molecular Sciences. – 2013. – Vol. 14, № 6. – P. 11145–11156. 27. PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level / L. Cao, X. Wang, S. Li [et al.] // Journal of Cancer. – 2017. – Vol. 8, № 16. P. 3251–3260. 28. Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis / S. Zang, Q. He, Q. Bao [et al.] // International Journal of Clinical Oncology. – 2019. – Vol. 24, № 9. P. 1049–1060. 29. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer / A. Cho, J. Hur, Y. J . Hong [et al.] // Tumour Biology. – 2016. – Vol. 37, № 3. – P. 3205–3213. 30. Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer / M. Muller, R. Hoogendoorn, R. J. G. Moritz [et al.] // Tumour Biology. – 2021. – Vol. 43, № 1. – P. 115–127. 31. CEA, CYFRA 21-1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach / C. Gruber, R. Hatz, J. Reinmiedl [et al.] // Journal of Laboratory Medicine. – 2008. – Vol. 32, № 5. – P. 361–371. 32. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer / M. Tiseo, A. Ardizzoni, M. A. Cafferata [et al.] // Anticancer Research. – 2008. – Vol. 28, № 1В. – P. 507–513. 33. Yan, H. J. Neuron specific enolase and prognosis of non-small cell lung cancer: a systematic review and metaanalysis / H. J. Yan, Y. Tan, W. Gu // Journal of the Balkan Union of Oncology. – 2014. – Vol. 19, № 1. – P. 153–156. 34. Early serum tumor marker dynamics predict progressionfree and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study / D. Lang, A. Horner, E. Brehm [et al.] // Lung Cancer. – 2019. – Vol. 134. – P. 59–65. 35. The role of CEA, CYFRA 21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients / M. G. Dal Bello, R. A. Filiberti, A. Alama [et al.] // Journal of Translational Medicine. – 2019. – Vol. 17, № 1. – 74. – DOI: 10.1186/s12967-019-1828-0. 36. Beauchemin, N. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis / N. Beauchemin, A. Arabzadeh // Cancer Metastasis Reviev. – 2013. – Vol. 32, № 3–4. – P. 643–671. 37. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors / R. Molina, X. Filella, J. M. Auge [et al.] // Tumour Biology. – 2003. – Vol. 24, № 4. – P. 209–218. 38. Pathologic stage I non-small cell lung can-cer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis / H. Matsuguma, R. Nakahara, S. Igarashi [et al.] // The Journal of Thoracic and Cardiovascular Surgery. – 2008. – Vol. 135, № 1. – P. 44–49. 39. Preoperative CYFRA 21–1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score / F. Blankenburg, R. Hatz, D. Nagel [et al.] // Tumour Biology. – 2008. – Vol. 29, № 4. – P. 272–277. 40. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma / H. J. Chen, C. Y. Tu, K. Y. Huang [et al.] // PLoS One. – 2020. – Vol. 15, № 12. – Р. e0240736. – doi: 10.1371/journal.pone.0240736. 41. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect / W. Yang, Y. Zheng, Y. Xia [et al.] // Nature Cell Biology. – 2012. – Vol. 14. – P. 1295–1304. 42. Pyruvate kinase M2 is a phosphotyrosine-binding protein / H. R. Christofk, M. G. Vander Heiden, N. Wu [et al.] // Nature. – 2008. – Vol. 452. – P. 181–186. 43. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis / R. Li, J. Liu, H. Xue, G. Huang // International Journal of Cancer. – 2012. – Vol. 131, № 8. – P. 1837–1845. 44. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases / J. Sneider, H. Morr, H. G. Velcovsky [et al.] // Cancer Detection and Prevention. – 2000. – Vol. 24. – P. 531–535. 45. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients; a further tool to define the need for invasive procedures / S. Elia, R. Massaud, G. Guggino [et al.] // European Journal of Cardio-Thoracic Surgery. – 2008. – Vol. 33, № 4. – P. 723–727. 46. Limited clinical significance of dimeric form of Pyruvate Kinase as a diagnostic and prognostic biomarker in non-small cell lung cancer / A. Rzechonek, A. Kaminska, P. Mamczur [et al.] // Advances in Experimental Medicine and Biology. – 2017. – Vol. 955. – P. 51–57. 47. Blood-based protein biomarker panel for the detection of colorectal cancer / K. Y. Fung, B. Tabor, M. J. Buckley [et al.] // PLoS One. – 2015. – Vol. 10, № 3. – Р. e0120425. – doi: 10.1371/journal.pone.0120425. 48. Pro-gastrin-releasing peptide in patients with benign and malignant diseases / R. Molina, J. M. Auge, J. Alicarte [et al.] // Tumour Biology. – 2004. – Vol. 25, № 1–2. – P. 56–61.